口服药-话题@MedSci

#口服药#

62篇内容 | 1974人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2060893, encodeId=6f1c206089358, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=先声制药新冠病毒3CL口服药物SIM0417首例患者入组, objectType=article, longId=724228, objectId=a17ae24228f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a17ae24228f4, replyNumber=0, likeNumber=80, createdTime=2022-07-09, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a17ae24228f4, moduleTitle=先声制药新冠病毒3CL口服药物SIM0417首例患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a17ae24228f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060888, encodeId=67702060888c5, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=我国自主研发的抗新冠口服药 VV116 启动三期临床研究, objectType=article, longId=300977, objectId=fd013009e7ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd013009e7ec, replyNumber=0, likeNumber=63, createdTime=2022-05-17, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd013009e7ec, moduleTitle=我国自主研发的抗新冠口服药 VV116 启动三期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd013009e7ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060884, encodeId=c964206088410, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=重磅！辉瑞新冠病毒口服药物Paxlovid，国内获附条件批准, objectType=article, longId=295532, objectId=6d76295532fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d76295532fc, replyNumber=0, likeNumber=96, createdTime=2022-09-12, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d76295532fc, moduleTitle=重磅！辉瑞新冠病毒口服药物Paxlovid，国内获附条件批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d76295532fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060890, encodeId=91e8206089002, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=STTT：羟甲香豆素可能对新冠重症治疗有益！有望研发新冠口服药, objectType=article, longId=301346, objectId=bb89301346e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb89301346e1, replyNumber=0, likeNumber=72, createdTime=2022-03-29, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb89301346e1, moduleTitle=STTT：羟甲香豆素可能对新冠重症治疗有益！有望研发新冠口服药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb89301346e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060886, encodeId=df812060886d3, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=曹彬教授：辉瑞新冠口服药只建议用于高危新冠感染患者, objectType=article, longId=299363, objectId=f1eb29936352, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1eb29936352, replyNumber=0, likeNumber=65, createdTime=2023-01-17, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1eb29936352, moduleTitle=曹彬教授：辉瑞新冠口服药只建议用于高危新冠感染患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1eb29936352)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060897, encodeId=4a01206089e8c, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=国产新冠口服药VV116对比PAXLOVID三期临床试验获得成功, objectType=article, longId=727732, objectId=4596e27732ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4596e27732ba, replyNumber=0, likeNumber=93, createdTime=2022-08-24, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4596e27732ba, moduleTitle=国产新冠口服药VV116对比PAXLOVID三期临床试验获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4596e27732ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060899, encodeId=4178206089972, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=最新宣布！首个SMA口服药利司扑兰主动大降价，百亿市场迎变, objectType=article, longId=729128, objectId=3c1ee2912891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c1ee2912891, replyNumber=0, likeNumber=0, createdTime=2023-05-16, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c1ee2912891, moduleTitle=最新宣布！首个SMA口服药利司扑兰主动大降价，百亿市场迎变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c1ee2912891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060875, encodeId=a01e20608e54c, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=2021年10月26日简报：湖北、浙江、海南等地启动3-11岁人群新冠病毒疫苗接种；欧洲药品管理局开始滚动审查默沙东新冠口服药物, objectType=article, longId=219276, objectId=11432192e670, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11432192e670, replyNumber=0, likeNumber=85, createdTime=2022-06-11, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11432192e670, moduleTitle=2021年10月26日简报：湖北、浙江、海南等地启动3-11岁人群新冠病毒疫苗接种；欧洲药品管理局开始滚动审查默沙东新冠口服药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11432192e670)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060878, encodeId=4ddd20608e84d, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=终结新冠！辉瑞新冠口服药物Paxlovid降低住院或死亡率89%！即使是出现症状5天内，仍然极其有效！, objectType=article, longId=219868, objectId=145b21986877, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=145b21986877, replyNumber=0, likeNumber=70, createdTime=2022-01-01, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=145b21986877, moduleTitle=终结新冠！辉瑞新冠口服药物Paxlovid降低住院或死亡率89%！即使是出现症状5天内，仍然极其有效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=145b21986877)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060873, encodeId=f03220608e39b, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=mRNA疫苗保护力5个月后大幅降低，首款新冠口服药即将获批 | 新冠研究新近进展, objectType=article, longId=218380, objectId=86992183805b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86992183805b, replyNumber=0, likeNumber=84, createdTime=2022-07-05, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86992183805b, moduleTitle=mRNA疫苗保护力5个月后大幅降低，首款新冠口服药即将获批 | 新冠研究新近进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86992183805b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060889, encodeId=be212060889a8, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=刚刚！2.12万盒新冠口服药Paxlovid在上海通关，火速运往抗疫一线！, objectType=article, longId=301094, objectId=c51630109442, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c51630109442, replyNumber=0, likeNumber=71, createdTime=2022-12-31, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c51630109442, moduleTitle=刚刚！2.12万盒新冠口服药Paxlovid在上海通关，火速运往抗疫一线！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c51630109442)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060872, encodeId=8d4720608e2c5, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=2021年10月10日简报：年底时可能有多款新冠病毒治疗口服药问世；安徽、福建、湖北、黑龙江、海南、广西、浙江、河南等地启动加强针；新西兰正式宣布同新冠共存, objectType=article, longId=218362, objectId=c7dc21836238, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7dc21836238, replyNumber=0, likeNumber=92, createdTime=2022-01-31, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7dc21836238, moduleTitle=2021年10月10日简报：年底时可能有多款新冠病毒治疗口服药问世；安徽、福建、湖北、黑龙江、海南、广西、浙江、河南等地启动加强针；新西兰正式宣布同新冠共存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7dc21836238)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060896, encodeId=47a920608969b, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=EMI：张文宏团队公布新冠口服药物VV116治疗效果, objectType=article, longId=727336, objectId=7cd8e27336f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cd8e27336f0, replyNumber=0, likeNumber=85, createdTime=2022-10-10, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cd8e27336f0, moduleTitle=EMI：张文宏团队公布新冠口服药物VV116治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cd8e27336f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060892, encodeId=a71320608929f, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=开拓药业新冠口服药普克鲁胺全球多中心三期临床成功（有点评）, objectType=article, longId=723632, objectId=b0e5e23632a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0e5e23632a1, replyNumber=0, likeNumber=67, createdTime=2023-02-28, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0e5e23632a1, moduleTitle=开拓药业新冠口服药普克鲁胺全球多中心三期临床成功（有点评）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0e5e23632a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060891, encodeId=34f5206089133, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=新冠口服药物Paxlovid，中国售价达2300元一盒！, objectType=article, longId=301777, objectId=0702301e77cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0702301e77cf, replyNumber=0, likeNumber=87, createdTime=2022-04-17, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0702301e77cf, moduleTitle=新冠口服药物Paxlovid，中国售价达2300元一盒！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0702301e77cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060871, encodeId=96f320608e1f3, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=2021年10月7日简报：张文宏认为新冠结束时间已不远！口服药，加强针成为全球重新开放的保障；全球新增新冠确诊病例和死亡人数继续下降, objectType=article, longId=218198, objectId=1ad021819871, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ad021819871, replyNumber=0, likeNumber=82, createdTime=2022-06-13, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ad021819871, moduleTitle=2021年10月7日简报：张文宏认为新冠结束时间已不远！口服药，加强针成为全球重新开放的保障；全球新增新冠确诊病例和死亡人数继续下降, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ad021819871)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060870, encodeId=051820608e0ad, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=2021年10月6日简报：美国民众反智，奇葩新冠阴谋论流行，大批民众拒绝接种疫苗；欧洲药品管理局可能开始加速评估默克的新冠口服药；新西兰宣布放弃“彻底消除新冠”战略, objectType=article, longId=218164, objectId=c13c2181649c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c13c2181649c, replyNumber=0, likeNumber=78, createdTime=2021-12-28, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c13c2181649c, moduleTitle=2021年10月6日简报：美国民众反智，奇葩新冠阴谋论流行，大批民众拒绝接种疫苗；欧洲药品管理局可能开始加速评估默克的新冠口服药；新西兰宣布放弃“彻底消除新冠”战略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c13c2181649c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060879, encodeId=6f0520608e9f7, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=2021年11月6日简报：辉瑞新冠口服药物Paxlovid降低住院或死亡率89%！有望终结新冠；中国内地31省份新冠疫苗接种超23亿剂次；, objectType=article, longId=219883, objectId=7bca2198830a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bca2198830a, replyNumber=0, likeNumber=81, createdTime=2021-12-14, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bca2198830a, moduleTitle=2021年11月6日简报：辉瑞新冠口服药物Paxlovid降低住院或死亡率89%！有望终结新冠；中国内地31省份新冠疫苗接种超23亿剂次；, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bca2198830a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060895, encodeId=adde20608954e, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=辉瑞新冠口服药Paxlovid用于暴露后预防的II/III期临床失败, objectType=article, longId=725951, objectId=a6bfe25951ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6bfe25951ed, replyNumber=0, likeNumber=134, createdTime=2022-12-03, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6bfe25951ed, moduleTitle=辉瑞新冠口服药Paxlovid用于暴露后预防的II/III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6bfe25951ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060894, encodeId=bdf1206089449, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, objectTitle=WHO更新新冠治疗指南！针对轻症，只有这种口服药被强烈推荐, objectType=article, longId=724835, objectId=d2fce2483539, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2fce2483539, replyNumber=0, likeNumber=82, createdTime=2022-07-21, rootId=0, userName=gdsun, userId=ed25376, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2fce2483539, moduleTitle=WHO更新新冠治疗指南！针对轻症，只有这种口服药被强烈推荐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2fce2483539)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

口服药

2020-05-29

gdsun (审核中...)

前往app查看评论内容

#口服药#

先声制药新冠病毒3CL口服药物SIM0417首例患者入组

2022-07-09

gdsun (审核中...)

前往app查看评论内容

#口服药#

我国自主研发的抗新冠口服药 VV116 启动三期临床研究

2022-05-17

gdsun (审核中...)

前往app查看评论内容

#口服药#

重磅！辉瑞新冠病毒口服药物Paxlovid，国内获附条件批准

2022-09-12

gdsun (审核中...)

前往app查看评论内容

#口服药#

STTT：羟甲香豆素可能对新冠重症治疗有益！有望研发新冠口服药

2022-03-29

gdsun (审核中...)

前往app查看评论内容

#口服药#

曹彬教授：辉瑞新冠口服药只建议用于高危新冠感染患者

2023-01-17

gdsun (审核中...)

前往app查看评论内容

#口服药#

国产新冠口服药VV116对比PAXLOVID三期临床试验获得成功

2022-08-24

gdsun (审核中...)

前往app查看评论内容

#口服药#

最新宣布！首个SMA口服药利司扑兰主动大降价，百亿市场迎变

2023-05-16

gdsun (审核中...)

前往app查看评论内容

#口服药#

2021年10月26日简报：湖北、浙江、海南等地启动3-11岁人群新冠病毒疫苗接种；欧洲药品管理局开始滚动审查默沙东新冠口服药物

2022-06-11

gdsun (审核中...)

前往app查看评论内容

#口服药#

终结新冠！辉瑞新冠口服药物Paxlovid降低住院或死亡率89%！即使是出现症状5天内，仍然极其有效！

2022-01-01

gdsun (审核中...)

前往app查看评论内容

#口服药#

mRNA疫苗保护力5个月后大幅降低，首款新冠口服药即将获批 | 新冠研究新近进展

2022-07-05

gdsun (审核中...)

前往app查看评论内容

#口服药#

刚刚！2.12万盒新冠口服药Paxlovid在上海通关，火速运往抗疫一线！

2022-12-31

gdsun (审核中...)

前往app查看评论内容

#口服药#

2021年10月10日简报：年底时可能有多款新冠病毒治疗口服药问世；安徽、福建、湖北、黑龙江、海南、广西、浙江、河南等地启动加强针；新西兰正式宣布同新冠共存

2022-01-31

gdsun (审核中...)

前往app查看评论内容

#口服药#

EMI：张文宏团队公布新冠口服药物VV116治疗效果

2022-10-10

gdsun (审核中...)

前往app查看评论内容

#口服药#

开拓药业新冠口服药普克鲁胺全球多中心三期临床成功（有点评）

2023-02-28

gdsun (审核中...)

前往app查看评论内容

#口服药#

新冠口服药物Paxlovid，中国售价达2300元一盒！

2022-04-17

gdsun (审核中...)

前往app查看评论内容

#口服药#

2021年10月7日简报：张文宏认为新冠结束时间已不远！口服药，加强针成为全球重新开放的保障；全球新增新冠确诊病例和死亡人数继续下降

2022-06-13

gdsun (审核中...)

前往app查看评论内容

#口服药#

2021年10月6日简报：美国民众反智，奇葩新冠阴谋论流行，大批民众拒绝接种疫苗；欧洲药品管理局可能开始加速评估默克的新冠口服药；新西兰宣布放弃“彻底消除新冠”战略

2021-12-28

gdsun (审核中...)

前往app查看评论内容

#口服药#

2021年11月6日简报：辉瑞新冠口服药物Paxlovid降低住院或死亡率89%！有望终结新冠；中国内地31省份新冠疫苗接种超23亿剂次；

2021-12-14

gdsun (审核中...)

前往app查看评论内容

#口服药#

辉瑞新冠口服药Paxlovid用于暴露后预防的II/III期临床失败

2022-12-03

gdsun (审核中...)

前往app查看评论内容

#口服药#

WHO更新新冠治疗指南！针对轻症，只有这种口服药被强烈推荐

2022-07-21

科室
- - 订阅+
  - 更多科室
工具
服务